Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.75 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871979 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL18922786 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL17777260 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL19549010 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL3694684 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL19565572 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL7996253 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL20980004 | 1.00 | VDR (0.82) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL18576030 | 0.94 | VDR (0.73) | VDRUSP2CYP2C9HIF1AGPBAR1 | |
| SCHEMBL31504641 | 0.94 | VDR (0.76) | VDRUSP2CYP2C9HIF1AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161102-B2 | Iminium salt organocatalysts, method of making, and methods of using | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190344253-A1 | IMINIUM SALT ORGANOCATALYSTS, METHOD OF MAKING, AND METHODS OF USING | UNIV VIRGINIA PATENT FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-10131688-B2 | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators | NZP UK Limited (GB) | 2018-11-20 | — | — | US | disclosed |
| US-20170327531-A1 | 6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LTD (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170320907-A1 | 5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | DEXTRA LABORATORIES LTD (GB) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320907-A1 | 5.BETA.-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NR1H4, CYP7A1, GPBAR1 | VDR 108/4885USP2 4557/4885CYP2C9 151/4885 |
| US-20170327531-A1 | 6.ALPHA.-ALKYL-6,7-DIONE STEROIDS AS INTERMEDIATES FOR THE PRODUCTION OF STEROIDAL FXR MODULATORS | NR1H4, CYP7A1, CYP7B1 | VDR 94/4885USP2 4572/4885CYP2C9 182/4885 |
| US-10131688-B2 | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators | NR1H4, CYP7A1, GPBAR1 | VDR 108/4885USP2 4557/4885CYP2C9 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.